broadli line key growth progress nice
report rel in-lin sale forecast core
franchis outperform keytruda deliv anoth solid quarter sale
beat rais global sale forecast
reflect faster expect uptak front-lin lung cancer aid
factor fx pushes/pul loe loss-of-exclus product slightli
increas sale ep driven higher keytruda sale out-year
make modest downward tweak earn increas non-gaap ep
mid-singl digit reflect greater share buyback follow announc
acceler share repurchas asr reiter buy rate po offer
upsid potenti vs consensu keytruda doubl digit ep compound-annual-growth-rate upsid
sever keytruda clinic data readout view
takeaway call
takeaway truda growth remain strong driven launch larg lung
cancer market us lung sale total us grew q/q share
new patient went broader indic treatment
lung cancer base keynot studi start benefit eu keytruda
next month gardasil vaccin sale growth strong y/i
meaning beat our/street forecast vs bofaml china launch
flag meaning contributor management comment franchis
long run rate growth ahead op margin expans management continu frame
meaning opportun time declin put paramet
timing/scop rel current consensu call bp margin
expans level strateg focu management continu view
anim health core busi synergist human health
compani announc buy-back program asr compani emphas
 remain high prioriti key catalyst detail data
rcc kidney cancer keytruda/inlyta combo like asco-gu februari aacr
meet april data neo-adjuv tripl neg breast cancer
net dbt
in-lin encourag perform
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
global pharma compani focus
discov develop market drug
infecti diseas oncolog
indic compani global leader
vaccin diversifi anim
rate buy offer attract valuat
good track record return cash
sharehold diversifi revenu base
substanti pipelin potenti keytruda
price object po base blend averag risk-adjust
discount cash flow dcf price-to-earnings multipl appli ep dcf assum
wacc termin growth rate believ dcf assumpt reason
given minim contribut new keytruda indic yet
valid late-stag clinic studi erod revenu base januvia/janumet
zepati neg termin growth target price-to-earnings multipl
base regress analysi histor us major pharma forward price-to-earnings
multipl three-year forward compound-annual-growth-rate non-gaap ep
risk competitor report result look substanti better
shown keytruda chemotherapi higher-than-anticip price pressur
diabet franchis neg result late-stag clinic program
jason gerberri herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us major specialti pharmaceut coverag cluster
compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
